FI903665A0 - Klonade gener som kodar ig-cd4-fusionsproteiner och deras anvaendning. - Google Patents

Klonade gener som kodar ig-cd4-fusionsproteiner och deras anvaendning.

Info

Publication number
FI903665A0
FI903665A0 FI903665A FI903665A FI903665A0 FI 903665 A0 FI903665 A0 FI 903665A0 FI 903665 A FI903665 A FI 903665A FI 903665 A FI903665 A FI 903665A FI 903665 A0 FI903665 A0 FI 903665A0
Authority
FI
Finland
Prior art keywords
fusionsproteiner
clonade
gener
immunoglobulin
siv
Prior art date
Application number
FI903665A
Other languages
English (en)
Finnish (fi)
Inventor
Brian Seed
Original Assignee
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp filed Critical Gen Hospital Corp
Publication of FI903665A0 publication Critical patent/FI903665A0/fi
Priority to FI954611A priority Critical patent/FI954611A0/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FI903665A 1988-01-22 1990-07-20 Klonade gener som kodar ig-cd4-fusionsproteiner och deras anvaendning. FI903665A0 (fi)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FI954611A FI954611A0 (fi) 1988-01-22 1995-09-28 Ig-CD4-fuusioproteiineja ja niiden käyttö HIV:n tai SIV:n havaitsemiseksi

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14735188A 1988-01-22 1988-01-22
PCT/US1989/000238 WO1989006690A1 (en) 1988-01-22 1989-01-23 Cloned genes encoding ig-cd4 fusion proteins and the use thereof

Publications (1)

Publication Number Publication Date
FI903665A0 true FI903665A0 (fi) 1990-07-20

Family

ID=22521217

Family Applications (1)

Application Number Title Priority Date Filing Date
FI903665A FI903665A0 (fi) 1988-01-22 1990-07-20 Klonade gener som kodar ig-cd4-fusionsproteiner och deras anvaendning.

Country Status (12)

Country Link
EP (1) EP0325262B1 (de)
JP (1) JP2980928B2 (de)
KR (1) KR900700606A (de)
AT (1) ATE102996T1 (de)
DE (1) DE68913771T2 (de)
DK (1) DK174190A (de)
ES (1) ES2051897T3 (de)
FI (1) FI903665A0 (de)
IE (1) IE63186B1 (de)
PT (1) PT89484B (de)
WO (1) WO1989006690A1 (de)
ZA (1) ZA89430B (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5336603A (en) * 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US6710169B2 (en) 1987-10-02 2004-03-23 Genentech, Inc. Adheson variants
ZA887365B (en) * 1987-10-02 1990-05-30 Genentech Inc Adheson variants
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US6406697B1 (en) 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
EP0394827A1 (de) * 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimärische CD4-Immunoglobulin-Polypeptide
FR2650598B1 (fr) * 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
WO1991002743A1 (en) * 1989-08-23 1991-03-07 The General Hospital Corporation Non-human primate cd4 polypeptides, fusions thereof, dna encoding, and uses thereof
EP0417563B1 (de) 1989-09-12 2000-07-05 F. Hoffmann-La Roche Ag TNF-bindende Proteine
JP2009165489A (ja) * 1989-11-22 2009-07-30 Genentech Inc リガンド結合タンパク質および安定血漿タンパク質からなる融合タンパク質
JPH0725794B2 (ja) * 1990-03-23 1995-03-22 呉羽化学工業株式会社 新規なペプチド
US6458360B1 (en) 1990-04-25 2002-10-01 The Johns Hopkins University Soluble complement regulatory molecules
IL97996A0 (en) * 1990-04-30 1992-06-21 Novo Nordisk As Hybrid cellular receptor
DK106490D0 (da) * 1990-04-30 1990-04-30 Novo Nordisk As Celle
DK0464533T3 (da) * 1990-06-28 1999-04-26 Gen Hospital Corp Fusionsproteiner med immunglobulindele, deres fremstilling og anvendelse
US7253264B1 (en) 1990-06-28 2007-08-07 Sanofi-Arentideutschland GmbH Immunoglobulin fusion proteins, their production and use
ES2171392T3 (es) * 1990-08-29 2002-09-16 Ct Hospitalier Regional De Nan Poliligandos de proteina unidos a un nucleo de proteina estable.
GB9022543D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Antibody production
DE4037837A1 (de) * 1990-11-28 1992-06-04 Behringwerke Ag Zellfreie rezeptorbindungsteste, ihre herstellung und verwendung
CA2080226C (en) 1991-02-08 2004-05-04 Gary A. Beaudry Cd4-gamma2 and cd4-igg2 chimeras
US7070991B2 (en) 1991-02-08 2006-07-04 Progenics Pharmaceuticals, Inc. Cells expressing a CD4-IgG2 chimeric heterotetramer
US5851828A (en) * 1991-03-07 1998-12-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
US6004811A (en) 1991-03-07 1999-12-21 The Massachussetts General Hospital Redirection of cellular immunity by protein tyrosine kinase chimeras
US6753162B1 (en) 1991-03-07 2004-06-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
US7049136B2 (en) 1991-03-07 2006-05-23 The General Hospital Corporation Redirection of cellular immunity by receptor chimeras
WO1992016622A1 (en) * 1991-03-12 1992-10-01 Biogen, Inc. Cd2-binding domain of lymphocyte function associated antigen 3
MX9203138A (es) * 1991-03-12 1992-09-01 Biogen Inc Dominio de enlace cd2-de antigeno 3 (lfa-3) asociado con funcion linfositos.
ATE170559T1 (de) * 1991-05-31 1998-09-15 Genentech Inc Behandlung der hiv-assoziierten immun- thrombopenie purpura
EP0533006A1 (de) * 1991-09-18 1993-03-24 F.Hoffmann-La Roche & Co. Aktiengesellschaft Chimäre Interleukin 5-Rezeptor/Immunoglobulin-Polypeptide
US6764681B2 (en) 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
CA2141673A1 (en) 1992-08-07 1994-02-17 Graham P. Allaway Non-peptidyl moiety-conjugated cd4-gamma2 and cd4-igg2 immunoconjugates, and uses thereof
DE4228839A1 (de) 1992-08-29 1994-03-03 Behringwerke Ag Verfahren zum Nachweis und zur Bestimmung von Mediatoren
AU5610194A (en) 1992-11-16 1994-06-08 Centocor Inc. Compounds having reduced immunogenicity and a method of reducing the immunogenicity of compounds
PT781095E (pt) * 1994-08-02 2003-06-30 Gen Hospital Corp Celulas contendo receptores chamariz cd4 e moleculas e metodos com elas relacionados
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
DE19826307A1 (de) * 1998-03-08 1999-12-16 Wolfgang Bergter CD4-Radioimmunpharmaka zur Behandlung der HIV-Infektion
US7311920B1 (en) 1999-10-08 2007-12-25 University Of Maryland Biotechnology Institute Virus coat protein/receptor chimeras and methods of use
ES2284532T3 (es) * 1999-10-08 2007-11-16 University Of Maryland Biotechnology Institute Quimeras de proteina de envuelta viral/receptor y metodos de uso.
US6908612B2 (en) 1999-10-08 2005-06-21 University Of Maryland Biotechnology Institute Virus coat protein/receptor chimeras and methods of use
CA2405557C (en) 2000-04-12 2013-09-24 Human Genome Sciences, Inc. Albumin fusion proteins
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
AU2002320352A1 (en) 2001-07-24 2003-02-17 Biogen Idec Ma Inc. Methods for treating or preventing sclerotic disorders using cd2-binding agents
ES2545090T3 (es) 2001-12-21 2015-09-08 Human Genome Sciences, Inc. Proteínas de fusión de albúmina y GCSF
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
AU2016244273B2 (en) * 2003-05-06 2018-10-18 Bioverativ Therapeutics Inc. Immunoglobulin Chimeric Monomer-Dimer Hybrids
AU2012200470B2 (en) * 2003-05-06 2014-12-18 Bioverativ Therapeutics Inc. Immunoglobulin Chimeric Monomer-Dimer Hybrids
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
ES2558102T3 (es) 2003-05-06 2016-02-02 Biogen Hemophilia Inc. Proteínas quiméricas del factor de coagulación para el tratamiento de un trastorno hemostático
DE102004017008B4 (de) 2004-04-02 2009-10-22 Aloys Wobben Verfahren zum Errichten eines Turmes
EP1750747A1 (de) 2004-05-07 2007-02-14 Astellas US LLC Lösliches lfa-3 polypeptid zur behandlung viraler erkrankungen
WO2010122148A1 (en) * 2009-04-24 2010-10-28 Boehringer Ingelheim International Gmbh An improved antibody domain and antibody fragments and antibodies based thereon
DE102013202353B4 (de) * 2013-02-13 2020-02-20 Adidas Ag Sohle für einen Schuh
CN112933952B (zh) * 2021-02-02 2021-10-22 东莞市科伟环保电力有限公司 一种基于大数据的pncr脱硝优化系统

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US104329A (en) * 1870-06-14 Improvement in warpiitg machines
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL87647A0 (en) * 1987-09-04 1989-02-28 Biogen Inc Dna sequences,recombinant dna molecules and processes for producing soluble t4 proteins
NZ226414A (en) * 1987-10-02 1992-07-28 Genentech Inc Cd4 peptide adhesion variants and their preparation and use

Also Published As

Publication number Publication date
IE63186B1 (en) 1995-03-22
JP2980928B2 (ja) 1999-11-22
ES2051897T3 (es) 1994-07-01
JPH03502283A (ja) 1991-05-30
KR900700606A (ko) 1990-08-16
EP0325262A3 (en) 1990-05-16
EP0325262B1 (de) 1994-03-16
DK174190D0 (da) 1990-07-20
PT89484A (pt) 1989-10-04
IE890182L (en) 1989-07-22
PT89484B (pt) 1994-03-31
DK174190A (da) 1990-09-14
AU611551B2 (en) 1991-06-13
DE68913771D1 (de) 1994-04-21
WO1989006690A1 (en) 1989-07-27
EP0325262A2 (de) 1989-07-26
AU3281889A (en) 1989-08-11
ATE102996T1 (de) 1994-04-15
DE68913771T2 (de) 1994-08-18
ZA89430B (en) 1989-10-25

Similar Documents

Publication Publication Date Title
FI903665A0 (fi) Klonade gener som kodar ig-cd4-fusionsproteiner och deras anvaendning.
ATE182007T1 (de) Bestimmung der kompatibilität anhand von löslichem hla
FI20022285A (fi) Eristetty liukoinen CTL4A-proteiini, sitä sisältäviä fuusioproteiineja, sen ligandeja, sen tunnistavia monoklonaalisia vasta-aineita ja käyttötapoja
FI940270A0 (fi) Menetelmiä immuunivasteen säätelemiseksi käyttämällä CTLA4:ää sitovia molekyylejä ja IL4:ää sitovia molekyylejä
ES2045216T3 (es) Inmunoensayo y derivados polimeros de igg para la compensacion de factores de perturbacion en el inmunoensayo.
DE69937899D1 (de) Antikörper-serumprotein hybride
DE69504955D1 (de) Immunstimulierende monoklonale antikörper
KR900013986A (ko) 종양-관련항원에 대한 모노클로날 항체(MAb_s), 이의 제조방법 및 용도
DK0378175T3 (da) Diagnostisk påvisning under anvendelse af kimære antistoffer
DE3584035D1 (de) Nachweis von menschlichem cytomegalovirus-spezifischem igm.
FI920658A0 (fi) Cd4-polypeptider av icke-maenskliga primater, fusionsproteiner daerav, dna, som kodar foer dessa, samt deras anvaendningar.
Fasler et al. Electrophoretic properties of human IgG and its subclasses on sodium dodecyl-sulfate-polyacrylamide gel electrophoresis and immunoblots
DE68921360D1 (de) Monoklonale Antikörper von Mäusen gegen das gp41 Protein von menschlichem Immunmangelsyndrom-Virus.
Knight et al. Distribution of covalently bound and non-covalently bound secretory component on subclasses of rabbit secretory IgA
Fellous et al. The expression of human beta2 microglobulin on human spermatozoa
Bonagura et al. Monomeric (7S) IgM found in the serum of rheumatoid arthritis patients share idiotypes with pentameric (19S) monoclonal rheumatoid factors.
ATE137410T1 (de) Konjugate von ''pokeweed'' antiviralem protein und monoklonalen antikörpern
Rødahl et al. Analysis of circulating immune complexes from patients with ankylosing spondylitis by gel electrophoresis and immunoblotting using antiserum against a psoriasis associated retrovirus-like particle.
KR890702034A (ko) 자체 완비된 다중-면역 분석 진단시스템
ES2056041T3 (es) Procedimiento para la deteccion de anticuerpos y antigenos.
Ishay et al. Investigation of wasp venom: antigenic relationship
Tan-Wilson Hindrance in the simultaneous binding of two distinctly separate antibody populations to the hemoglobin antigen
EMONDS et al. An EIA method on single donor solubilized HLA antigens for the identification of anti‐HLA antibodies
Shanina et al. Analiz syvorotochnykh antitel k antigenam nervnoǐ tkani u bol'nykh bokovym amiotroficheskim sklerozom.
Boadde et al. CD21 augments antigen presentation in immune individuals

Legal Events

Date Code Title Description
FD Application lapsed

Owner name: THE GENERAL HOSPITAL CORPORATION